Thu, July 16, 2009
Wed, July 15, 2009
Tue, July 14, 2009
Mon, July 13, 2009
Fri, July 10, 2009
Thu, July 9, 2009
Wed, July 8, 2009
Tue, July 7, 2009
Mon, July 6, 2009
Fri, July 3, 2009
Thu, July 2, 2009
Wed, July 1, 2009
Tue, June 30, 2009
Mon, June 29, 2009
Fri, June 26, 2009
Thu, June 25, 2009
Wed, June 24, 2009
Tue, June 23, 2009
Mon, June 22, 2009
Sun, June 21, 2009
Fri, June 19, 2009
Thu, June 18, 2009
Wed, June 17, 2009
Tue, June 16, 2009
Mon, June 15, 2009
Fri, June 12, 2009
Thu, June 11, 2009
Wed, June 10, 2009
Tue, June 9, 2009
Mon, June 8, 2009
Sun, June 7, 2009
Fri, June 5, 2009
Thu, June 4, 2009
Wed, June 3, 2009
Tue, June 2, 2009
Mon, June 1, 2009
Sat, May 30, 2009
Fri, May 29, 2009
Thu, May 28, 2009
Wed, May 27, 2009
Tue, May 26, 2009
Mon, May 25, 2009
Fri, May 22, 2009
Thu, May 21, 2009
Wed, May 20, 2009
Tue, May 19, 2009
Mon, May 18, 2009
Fri, May 15, 2009
Thu, May 14, 2009
Wed, May 13, 2009
Tue, May 12, 2009
Mon, May 11, 2009
Fri, May 8, 2009
Thu, May 7, 2009
Thu, April 16, 2009
Wed, April 15, 2009
Tue, April 14, 2009

CTD Holdings, Inc.: CTD Holdings to Institutionalize Niemann-Pick C Efforts


//health-fitness.news-articles.net/content/2009/ .. -to-institutionalize-niemann-pick-c-efforts.html
Published in Health and Fitness on , Last Modified on 2009-06-08 05:16:54 by Market Wire   Print publication without navigation


HIGH SPRINGS, FL--(Marketwire - June 8, 2009) - CTD Holdings, Inc. (OTCBB: [ CTDH ]) (FRANKFURT: CDJ) announces the creation of an Ameliorative Therapies department within its wholly owned subsidiary, CTD Inc. This department, through the use of existing staff and independent consultants, will oversee the collection, collation and analysis of data on the ameliorative uses of Cyclo™ coming from existing and new compassionate use trials around the world.

CTDH is currently applying for Trademark protection for Cyclo™, a new product line to be used exclusively for research and compassionate use in conjunction with dysfunctional cholesterol metabolism ailments and diseases. Currently, the product is being used under an FDA approved compassionate use treatment for Niemann-Pick C patients.

"The Addi and Cassi Hempel (see [ www.WebofHope.com ]) compassionate use trial with Cyclo™ has initiated worldwide contacts from physicians treating Niemann-Pick C patients in the US, India, Lebanon, Spain, Japan, and China. Additionally, the medical research community in the US and England, specializing in cholesterol metabolism, are ordering Trappsol® (CTD's branded CDs) radiolabelled Cyclo™," stated Mr. C.E. Strattan (Pres/CEO). "It appears that Cyclo™'s role in dysfunctional cholesterol metabolism has come to the attention of some very qualified medical research faculties."

Dysfunctional cholesterol metabolism has been implicated in the etiology of Adult and Childhood Alzheimer's, HIV Aids, Coronary Artery Disease, and Diabetes. "Creating the conduit for the efficient collection of the compassionate use data will expedite routine use of Cyclo™ in ameliorative scenarios," promises Mr. Strattan.

About CTD Holdings, Inc.

The company is the one-stop shop, business to business facilitator of commercial and research applications of cyclodextrins. With its branded Trappsol® and Aquaplex® product offerings, CTDH scientists coordinate the development of commercial products for use in the pharmaceuticals, foods, hazardous waste treatment, and cosmetics industries, just to name a few of the industries which endeavor to put non water-soluble ingredients into water-based formulations. More recently CTDH has worked, in an advisory capacity, on the benefits and application of Cyclodextrins as a treatment for Niemann Picks disease, a debilitating childhood disease often associated with Alzheimer's. CTDH was founded in 1990 as a Florida corporation and became a public company in 1994. Additional information on the Company can be found on the Company's website: [ www.cyclodex.com ]

This news release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements. CTDH complies with the regulations and time lines mandated by the SEC in the filing of its financial reports; these filings also contain forward-looking statements. The above forward-looking statements are made as of the date above; CTD Holdings, Inc accepts no specific responsibility for updating such statements.


Publication Contributing Sources

Similar Health and Fitness Publications